drugset / Trial / NCT03542877
Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer
Phase 2
Completed
44 enrolled
Academic Thoracic Oncology Medical Investigators Consortium
University of Colorado, Denver · collab
NaSingle-groupOpen-labelTreatment
Summary
This study seeks to use Cabozantinib to treat those with Metastatic Colorectal Cancer who have not previously responded to treatment.
Timeline
- Start
- 2018-06-01
- Primary completion
- 2020-10-19
- Completion
- 2022-03-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | 60 mg | Oral |